Skip to content
Clinical Trials – home
SpainBack to Spain

Clinical trials in Pozuelo De Alarcon – page 101

3 275 clinical trials in Pozuelo De Alarcon, Spain across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Pozuelo De Alarcon at a glance
3 275
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

3 275 trials in Pozuelo De Alarcon

Open in trial search

Multifocal motor neuropathy

Not yet recruiting

Phase 1b study of empasiprubart in adults with multifocal motor neuropathy to assess nerve morphology by ultrasound

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Empasiprubart
  • Sponsor:Argenx

Hypersensitivity

Not yet recruiting

Standardization of Cynodon dactylon allergen extract for skin‑prick testing in patients with allergies

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Sodium Chloride
  • Sponsor:Asac Pharmaceutical Inmunology S.A.

Breast cancer+2

Not yet recruiting

Gedatolisib with drug combination versus standard therapy as first‑line treatment for patients with advanced HR‑positive HER2‑negative breast cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Celcuity Inc.

Prostate cancer metastatic

Not yet recruiting

Study of saruparib plus AR inhibitor drug combination in men with metastatic hormone‑sensitive prostate cancer previously treated with docetaxel or Lu‑PSMA and PSA ≥0.2 ng/mL

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:AstraZeneca AB

Adenocarcinoma gastric+1

Not yet recruiting

A Phase 3 Study of ASP2138 Plus Drug Combination in Adults with HER2‑Negative, CLDN18.2‑Positive Advanced Gastric Cancer (First‑Line Treatment)

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Astellas Pharma Global Development Inc.

Hypersomnia

Not yet recruiting

Long‑term Safety and Tolerability Study of TAK‑360 in Adults with Narcolepsy or Idiopathic Hypersomnia

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Sponsor:Takeda Development Center Americas Inc.

Neoplasm malignant

Not yet recruiting

Study of ARV-6723 Alone or with Pembrolizumab to Assess Safety and Early Effect in Adults with Advanced Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Arvinas Operations Inc.

C3 glomerulopathy

Not yet recruiting

Pegcetacoplan to Prevent Recurrence of C3 Glomerulopathy or Primary Immune‑Complex MPGN in Adolescent and Adult Kidney Transplant Recipients

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Pegcetacoplan
  • Sponsor:Swedish Orphan Biovitrum AB (publ)

Non-small cell lung cancer

Not yet recruiting

Phase 1/2 Study of VRN110755 to Assess Safety, Dose and Efficacy in Patients with EGFR‑mutant Non‑Small Cell Lung Cancer

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Sponsor:Voronoi Inc.

Phelan-McDermid syndrome

Not yet recruiting

Study of the Safety, Tolerability and Efficacy of Oral Vafidemstat in Adults with Phelan‑McDermid Syndrome (HOPE‑2)

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Vafidemstat
  • Sponsor:Oryzon Genomics S.A.

Gastric cancer

Not yet recruiting

Immune Modulation Study of Rilvegostomig and Pembrolizumab in Patients with Advanced Gastric Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Vall D Hebron Institute Of Oncology

Psychotic disorder+2

Not yet recruiting

A Randomized Controlled Trial of Cannabidiol vs Placebo Augmentation in Patients with First Episode Psychosis

Registered drug
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Cannabidiol
  • Sponsor:University Of Oxford

Other cities in Spain

The busiest research cities in the country

All 210 cities in Spain

Clinical research in Pozuelo De Alarcon

What the registry says about research in the country

01 Oncology Research

Innovative trials focusing on multiple cancer types including bladder cancer, pancreatic adenocarcinoma, and non-small cell lung cancer. Studies evaluate novel combination therapies and targeted treatments.

  • Advanced solid tumors
  • Metastatic melanoma
  • Gastric cancer

Research includes immunotherapy approaches and antibody-drug conjugates for improved treatment outcomes.

02 Respiratory Medicine

Clinical investigations in respiratory conditions, including studies of RSV prevention in high-risk infants and novel treatments for uncontrolled asthma. Research focuses on innovative therapeutic approaches.

  • COVID-19 vaccine development
  • Respiratory infections
  • Inflammatory airway diseases

Studies evaluate both preventive measures and treatment interventions.

03 Neurological Disorders

Research targeting neurological conditions, with emphasis on Alzheimer's Disease and Multiple Sclerosis. Studies focus on disease-modifying therapies and novel treatment approaches.

  • Early-stage Alzheimer's treatment
  • Relapsing MS therapies
  • Neurodegeneration

Investigations aim to slow disease progression and improve patient outcomes.

04 Hematology

Studies in blood disorders including acute myeloid leukemia and immune thrombocytopenia. Research evaluates new therapeutic approaches and combination treatments.

  • Leukemia treatments
  • Myelodysplastic syndrome
  • Platelet disorders

Focus on improving survival rates and treatment efficacy.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.